Cargando…

Influenza

Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses. Typically characterized by annual seasonal epidemics, sporadic pandemic outbreaks involve influenza A virus strains of zoonotic origin. The WHO estimates that annual epidemics of influen...

Descripción completa

Detalles Bibliográficos
Autores principales: Krammer, Florian, Smith, Gavin J. D., Fouchier, Ron A. M., Peiris, Malik, Kedzierska, Katherine, Doherty, Peter C., Palese, Peter, Shaw, Megan L., Treanor, John, Webster, Robert G., García-Sastre, Adolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097467/
https://www.ncbi.nlm.nih.gov/pubmed/29955068
http://dx.doi.org/10.1038/s41572-018-0002-y
_version_ 1783511005722050560
author Krammer, Florian
Smith, Gavin J. D.
Fouchier, Ron A. M.
Peiris, Malik
Kedzierska, Katherine
Doherty, Peter C.
Palese, Peter
Shaw, Megan L.
Treanor, John
Webster, Robert G.
García-Sastre, Adolfo
author_facet Krammer, Florian
Smith, Gavin J. D.
Fouchier, Ron A. M.
Peiris, Malik
Kedzierska, Katherine
Doherty, Peter C.
Palese, Peter
Shaw, Megan L.
Treanor, John
Webster, Robert G.
García-Sastre, Adolfo
author_sort Krammer, Florian
collection PubMed
description Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses. Typically characterized by annual seasonal epidemics, sporadic pandemic outbreaks involve influenza A virus strains of zoonotic origin. The WHO estimates that annual epidemics of influenza result in ~1 billion infections, 3–5 million cases of severe illness and 300,000–500,000 deaths. The severity of pandemic influenza depends on multiple factors, including the virulence of the pandemic virus strain and the level of pre-existing immunity. The most severe influenza pandemic, in 1918, resulted in >40 million deaths worldwide. Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift. Nevertheless, vaccine efficacy is not optimal and is dramatically low in the case of an antigenic mismatch between the vaccine and the circulating virus strain. Antiviral agents that target the influenza virus enzyme neuraminidase have been developed for prophylaxis and therapy. However, the use of these antivirals is still limited. Emerging approaches to combat influenza include the development of universal influenza virus vaccines that provide protection against antigenically distant influenza viruses, but these vaccines need to be tested in clinical trials to ascertain their effectiveness.
format Online
Article
Text
id pubmed-7097467
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70974672020-03-26 Influenza Krammer, Florian Smith, Gavin J. D. Fouchier, Ron A. M. Peiris, Malik Kedzierska, Katherine Doherty, Peter C. Palese, Peter Shaw, Megan L. Treanor, John Webster, Robert G. García-Sastre, Adolfo Nat Rev Dis Primers Primer Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses. Typically characterized by annual seasonal epidemics, sporadic pandemic outbreaks involve influenza A virus strains of zoonotic origin. The WHO estimates that annual epidemics of influenza result in ~1 billion infections, 3–5 million cases of severe illness and 300,000–500,000 deaths. The severity of pandemic influenza depends on multiple factors, including the virulence of the pandemic virus strain and the level of pre-existing immunity. The most severe influenza pandemic, in 1918, resulted in >40 million deaths worldwide. Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift. Nevertheless, vaccine efficacy is not optimal and is dramatically low in the case of an antigenic mismatch between the vaccine and the circulating virus strain. Antiviral agents that target the influenza virus enzyme neuraminidase have been developed for prophylaxis and therapy. However, the use of these antivirals is still limited. Emerging approaches to combat influenza include the development of universal influenza virus vaccines that provide protection against antigenically distant influenza viruses, but these vaccines need to be tested in clinical trials to ascertain their effectiveness. Nature Publishing Group UK 2018-06-28 2018 /pmc/articles/PMC7097467/ /pubmed/29955068 http://dx.doi.org/10.1038/s41572-018-0002-y Text en © Macmillan Publishers Ltd., part of Springer Nature 2018 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Primer
Krammer, Florian
Smith, Gavin J. D.
Fouchier, Ron A. M.
Peiris, Malik
Kedzierska, Katherine
Doherty, Peter C.
Palese, Peter
Shaw, Megan L.
Treanor, John
Webster, Robert G.
García-Sastre, Adolfo
Influenza
title Influenza
title_full Influenza
title_fullStr Influenza
title_full_unstemmed Influenza
title_short Influenza
title_sort influenza
topic Primer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097467/
https://www.ncbi.nlm.nih.gov/pubmed/29955068
http://dx.doi.org/10.1038/s41572-018-0002-y
work_keys_str_mv AT krammerflorian influenza
AT smithgavinjd influenza
AT fouchierronam influenza
AT peirismalik influenza
AT kedzierskakatherine influenza
AT dohertypeterc influenza
AT palesepeter influenza
AT shawmeganl influenza
AT treanorjohn influenza
AT websterrobertg influenza
AT garciasastreadolfo influenza